2024
Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and 0522
Corredor G, Harris J, Koyuncu C, Pathak T, Pandav K, Toro P, Yang K, Faraji F, Castro P, Sandulache V, Koyfman S, Nguyen F, Garden A, Caudell J, Jones C, Rosenthal D, Le Q, Lewis J, Madabhushi A. Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and 0522. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s130. DOI: 10.1016/j.ijrobp.2024.07.236.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesDisease-free survivalOverall survivalHazard ratioHPV+ OPSCCPoor survivalRisk of disease-free survivalOropharyngeal squamous cell carcinoma patientsDisease-free survival modelsSquamous cell carcinoma patientsTreated with standard therapyRisk of overall survivalAssociated with overall survivalHigh-risk ptsRisk scoreCell carcinoma patientsRisk of poor survivalSubsets of patientsCox regression modelsLow-risk counterpartsHPV-positivePrimary tumorCarcinoma patientsStandard therapyInstitutional cohortPD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, Bagheri A, Savla V, Nabil Laimon Y, Gupta S, Vemula S, Braun D, Burke K, Catalano P, Freeman G, Motzer R, Atkins M, McDermott D, Sharpe A, Choueiri T, Signoretti S. PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients. Clinical Cancer Research 2024, 30: 803-813. PMID: 38060202, PMCID: PMC10922154, DOI: 10.1158/1078-0432.ccr-23-2274.Peer-Reviewed Original ResearchPD-1 expressionObjective response rateProgression-free survivalLow objective response rateShorter progression-free survivalPD-1 blockadeRegulatory T cellsShorter overall survivalOverall survivalPD-1Nivolumab armT cellsMetastatic clear-cell renal cell carcinoma patientsMetastatic clear cell renal cell carcinomaAnti-PD-1 therapyIntratumoral regulatory T cellsClear cell renal cell carcinoma patientsRenal cell carcinoma patientsClear cell renal cell carcinomaPD-1 inhibitorsPD-1 inhibitionCell carcinoma patientsCell renal cell carcinomaExpression of CD8Tumor-infiltrating Tregs
2022
The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment
Yang Z, Lin H, Wang Z, Rong L, Zhang X, Wang L, Qin J, Xue X, Li Y, Xue L. The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment. BMC Cancer 2022, 22: 1180. PMID: 36384463, PMCID: PMC9670431, DOI: 10.1186/s12885-022-10276-1.Peer-Reviewed Original ResearchConceptsEsophageal squamous cell carcinomaEsophageal squamous cell carcinoma patientsRoyal College of Pathologists criteriaRoyal College of PathologistsCRM statusCollege of American PathologistsResection marginsPrognostic factorsPrognostic significancePrognostic valueSquamous cell carcinoma patientsLong-term prognostic significanceCircumferential resection marginCell carcinoma patientsCollege of American Pathologists criteriaSquamous cell carcinomaLymph node metastasisMultivariate survival analysisLong-term survivalPN0 subgroupPN3 subgroupsNeoadjuvant therapyNeoadjuvant treatmentPT3 tumorsTumor distanceFusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan , Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia 2022, 31: 100813. PMID: 35834946, PMCID: PMC9287628, DOI: 10.1016/j.neo.2022.100813.Peer-Reviewed Original ResearchConceptsPD-L1 expressionAdjacent normal tissuesWhole-exome sequencingNormal tissuesNeck cancerOral tongue squamous cell carcinoma patientsTongue squamous cell carcinoma patientsSquamous cell carcinoma patientsTumor samplesPD-L1 mRNA expressionPD-L1 protein expressionOral tongue SCCCell carcinoma patientsOral tongue cancerImmune cell infiltrationPD-L1 mRNATumor immune microenvironmentNeck SCC cell linesNeck cancer cell linesSCC cell linesDevelopment of headCell linesCancer cell linesTongue SCCCarcinoma patientsFirst-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical Cancer Research 2022, 28: of1-of12. PMID: 35699599, PMCID: PMC9662912, DOI: 10.1158/1078-0432.ccr-21-4020.Peer-Reviewed Original ResearchConceptsAdverse eventsImmune activationT cellsMost common treatment-related adverse eventsCommon treatment-related adverse eventsSolid tumorsTreatment-related adverse eventsRenal cell carcinoma patientsNon-small cell lung carcinomaRegulatory T cell functionTriple-negative breast cancerPD-1/PD-L1 antagonistsDose-escalation stageInfusion-related reactionsAdvanced solid tumorsRefractory solid tumorsCell carcinoma patientsDose-limiting toxicityEffector T cellsSubset of patientsFavorable safety profileHuman phase IPD-L1 antagonistsT cell functionCell lung carcinomaPET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients
Haider S, Sharaf K, Zeevi T, Mahajan A, Forghani R, Judson B, Kann B, Burtness B, Reichel C, Baumeister P, Payabvash S. PET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients. Laryngo-Rhino-Otologie 2022, 101: s184-s184. DOI: 10.1055/s-0042-1746471.Peer-Reviewed Original ResearchPatient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents
Spees LP, Dinan MA, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George DJ, Scales CD, Pritchard JE, Leapman M, Gross CP, Wheeler SB. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents. Clinical Genitourinary Cancer 2022, 20: e396-e405. PMID: 35595633, PMCID: PMC9529768, DOI: 10.1016/j.clgc.2022.04.010.Peer-Reviewed Original ResearchConceptsOral anticancer agentsCause mortalityReal-world populationHazard ratioComplex patientsMetastatic renal cell carcinoma patientsFDA approvalMetastatic renal cell carcinomaRenal cell carcinoma patientsProvider-level predictorsRetrospective cohort studyCell carcinoma patientsPatients' clinical characteristicsProvider-level factorsPivotal clinical trialsState Cancer RegistryRenal cell carcinomaCox hazard modelHigh-quality careAnticancer agentsProvider Enumeration SystemMRCC patientsClinical characteristicsCohort studyPatient characteristics
2021
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal Of Clinical Oncology 2021, 44: 495-501. PMID: 34432667, DOI: 10.1097/coc.0000000000000849.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRCC brain metastasesBrain metastasesRenal cell carcinomaStereotactic radiosurgeryOverall survivalUse of ICIsCentral nervous system toxicityRenal cell carcinoma patientsImpact of immunotherapyLocal control outcomesMedian overall survivalCell carcinoma patientsKaplan-Meier curvesNervous system toxicityBetter median OSLog-rank testMann-Whitney U testMargin doseMedian OSNonimmunotherapy groupSRS doseCheckpoint inhibitorsImmunotherapy groupCarcinoma patientsGene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent
Yang ES, Nassar AH, Adib E, Jegede OA, Alaiwi SA, Manna DLD, Braun DA, Zarei M, Du H, Pal SK, Naik G, Sonpavde GP. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics 2021, 20: 1454-1461. PMID: 34108261, DOI: 10.1158/1535-7163.mct-20-1091.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzofuransBiomarkers, TumorCarcinoma, Renal CellClinical Trials, Phase III as TopicEverolimusFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedOrganophosphatesPrognosisSurvival RateTranscriptomeValidation Studies as TopicConceptsMetastatic renal cell carcinomaMedian PFSClinical benefitDiscovery cohortMetastatic renal cell carcinoma patientsPhase I/II trialRenal cell carcinoma patientsPhase III trialsCell carcinoma patientsLonger median PFSRenal cell carcinomaFour-gene signaturePropensity score covariate adjustmentVascular Disrupting AgentsCheckMate 025Monotherapy useStable diseaseII trialGene expression signaturesIII trialsAppropriate patientsCarcinoma patientsImmune checkpointsCell carcinomaVEGF inhibitorsCirculating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
Esteban E, Exposito F, Crespo G, Lambea J, Pinto A, Puente J, Arranz JA, Redrado M, Rodriguez-Antona C, de Andrea C, Lopez-Brea M, Redin E, Rodriguez A, Serrano D, Garcia J, Grande E, Castellano D, Calvo A. Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers 2021, 13: 2849. PMID: 34200459, PMCID: PMC8201218, DOI: 10.3390/cancers13112849.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalOverall survivalIL-6MRCC patientsSerum levelsTumor expressionAntiangiogenic therapyMetastatic renal cell carcinoma patientsMultivariable Cox regression analysisStandard first-line treatmentC-MetRenal cell carcinoma patientsShorter progression-free survivalFirst-line treatmentCell carcinoma patientsCohort of patientsHigh tumor expressionIL-6 levelsBasal serum levelsCox regression analysisHigh basal serum levelsLevels of biomarkersRenal cell carcinomaDifferent Spanish hospitalsPatterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.
Wheeler S, Spees L, Jackson B, Baggett C, Wilson L, Greiner M, George D, Scales C, Pritchard J, Dinan M. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. Journal Of Clinical Oncology 2021, 39: 279-279. DOI: 10.1200/jco.2021.39.6_suppl.279.Peer-Reviewed Original ResearchMetastatic renal cell carcinoma patientsRenal cell carcinoma patientsCell carcinoma patientsOral anti-cancer agentsCarcinoma patientsRisk ratioPatterns of useRisk differenceGreater comorbidity burdenMetastatic RCC patientsPopulation-based studyPatient-level characteristicsMonths of preAdjusted risk differencePoor quality careComorbidity burdenIndex dateAnti-cancer agentsMetastatic RCCPatient characteristicsContinuous enrollmentRCC patientsTreatment advancesType of insurancePatientsNeoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
Bilen M, Jiang J, Jansen C, Brown J, Harik L, Sekhar A, Kissick H, Maithel S, Kucuk O, Carthon B, Master V. Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. Frontiers In Oncology 2021, 10: 622134. PMID: 33598435, PMCID: PMC7882722, DOI: 10.3389/fonc.2020.622134.Peer-Reviewed Original ResearchRenal cell carcinomaMetastatic renal cell carcinomaMagnetic resonance imagingSurgical resectionNeoadjuvant settingCell carcinomaAdvanced renal cell carcinoma patientsLocally advanced renal cell carcinomaLeft renal cell carcinomaUnresectable renal cell carcinomaAdvanced renal cell carcinomaInvasion of adjacent structuresRenal cell carcinoma patientsNeoadjuvant systemic therapySecond-line settingSplenic flexure of colonTumor size reductionCell carcinoma patientsTail of pancreasReduced tumor growthAdjacent structuresTyrosine kinase c-MetCABOSUN trialPosterior abdominal wallTumor diameter
2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.Peer-Reviewed Original ResearchConceptsCytoreductive nephrectomyPostoperative complicationsMultivariable analysisMRCC patientsIntraoperative complicationsBlood lossSignificant predictorsComplex surgeryMetastatic renal cell carcinoma patientsHigh-grade postoperative complicationsHigher intraoperative blood lossMetastatic renal cell carcinomaRenal cell carcinoma patientsCase loadHigh-grade morbidityMultiple postoperative complicationsIntraoperative blood lossMetastatic renal cancerCell carcinoma patientsPrimary kidney tumorsRenal cell carcinomaLogistic regression analysisTherapy eraPerioperative complicationsPostoperative morbidityCD4 T cell phenotypes differentially modulate the CD8 T cell response in kidney cancer
Cardenas M, Prokhnevska N, Jansen C, Master V, Kissick H. CD4 T cell phenotypes differentially modulate the CD8 T cell response in kidney cancer. The Journal Of Immunology 2020, 204: 165.1-165.1. DOI: 10.4049/jimmunol.204.supp.165.1.Peer-Reviewed Original ResearchTumor-infiltrating CD4 T cellsInfiltrating CD4 T cellsCD8 T cell responsesCD4 T cellsAnti-tumor responsesT cell responsesCD8 T cell infiltrationT cellsKidney cancer patientsTumor-specific CD8 T-cell responsesTumor-infiltrating CD8 T cellsSubsets of CD4 T cellsCancer patientsCD8 T cell functionMaster transcription factor Foxp3CD8 T cell differentiationCD4 T cell phenotypeRenal cell carcinoma patientsResponse to immunotherapyCD8 T cellsT cell infiltrationT regulatory cellsT-cell phenotypeCell carcinoma patientsTranscription factor Foxp3
2019
Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria
Hamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRisk of recurrenceRenal cell carcinomaKaplan-Meier analysisHigher clinical stageClinical stageOverall survivalMultivariable analysisPT3a upstagingRisk factorsTumor-NodeT3a renal cell carcinomaRenal cell carcinoma patientsRisk of upstagingCell carcinoma patientsMulticenter retrospective analysisPerinephric fat invasionInitial clinical stageRenal vein invasionType of surgeryPT3a diseaseCarcinoma patientsPrimary outcomeFat invasionRenal veinIs robotic surgery an option for early T‐stage laryngeal cancer? Early nationwide results
Hanna J, Brauer PR, Morse E, Judson B, Mehra S. Is robotic surgery an option for early T‐stage laryngeal cancer? Early nationwide results. The Laryngoscope 2019, 130: 1195-1201. PMID: 31233223, DOI: 10.1002/lary.28144.Peer-Reviewed Original ResearchConceptsTransoral robotic surgeryTransoral laser microsurgeryAdjuvant radiationOpen surgerySupraglottic patientsOverall survivalCox regressionMargin statusMultivariable analysisSurgical approachLaryngeal cancerLaryngeal squamous cell carcinoma patientsSquamous cell carcinoma patientsEarly-stage laryngeal cancerRobotic surgeryMultivariable Cox regressionNational Cancer DatabaseCell carcinoma patientsRetrospective database analysisViable treatment optionTORS patientsPartial surgeryMultivariable logisticCarcinoma patientsNegative marginsBenefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustmentTargeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma
Bergerot P, Bergerot C, Philip E, Meza L, Dizman N, Hsu J, Pal S. Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma. Kidney Cancer 2019, 3: 63-70. DOI: 10.3233/kca-180047.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorHigher body mass indexBody mass indexLower body mass indexMedian overall survivalOverall survivalMass indexMetastatic renal cell carcinoma patientsMetastatic renal cell carcinomaEffect of BMIRenal cell carcinoma patientsImproved overall survivalCell carcinoma patientsBetter overall survivalKaplan-Meier methodContext of immunotherapyRenal cell carcinomaPatients 66Median OSCarcinoma patientsClinical outcomesHigher BMIRetrospective studyCell carcinomaClinical variables
2018
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool
Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, Beal K, Rana NG, Attia A, Tseng CL, Sahgal A, Shanley R, Sperduto WA, Lou E, Zahra A, Buatti JM, Yu JB, Chiang V, Molitoris JK, Masucci L, Roberge D, Shi DD, Shih HA, Olson A, Kirkpatrick JP, Braunstein S, Sneed P, Mehta MP. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology 2018, 20: 1652-1660. PMID: 30418657, PMCID: PMC6231200, DOI: 10.1093/neuonc/noy099.Peer-Reviewed Original ResearchConceptsPrognostic assessment toolsBrain metastasesRenal cell carcinomaMedian survivalPrognostic factorsAdditional significant prognostic factorsRenal cell carcinoma patientsRetrospective institutional review boardNew brain metastasesKarnofsky performance statusOverall median survivalCell carcinoma patientsSignificant prognostic factorsFuture clinical trialsClinical decision makingInstitutional review boardAssessment toolPerformance statusCommon complicationExtracranial metastasesHazard ratioCarcinoma patientsContemporary cohortRCC patientsWorse prognosisPrevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.
Owonikoko T, Redman M, Byers L, Griffin K, Hirsch F, Mack P, Gandara D, Bradley J, Stinchcombe T, Kelly K, Ramalingam S, Herbst R, Papadimitrakopoulou V. Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study. Journal Of Clinical Oncology 2018, 36: 9055-9055. DOI: 10.1200/jco.2018.36.15_suppl.9055.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply